View Post

ASCO Endorses Some Complementary Therapies in Breast Cancer

In In The News by Barbara Jacoby

By: Roxanne Nelson, BSN, RN From: medscape.com Many cancer patients use alternative medicine, including supplements, massage therapy, yoga, and accupuncture, while undergoing conventional cancer care. Such therapies are usually acceptable, but patients must be discuss such therapies with their oncologist, because interactions may occur. That appears to be the take-home message from the recent move by the American Society of Clinical …

View Post

Most Women With Early Stage Breast Cancer Can Forgo Chemotherapy When Guided by a Diagnostic Test

In In The News by Barbara Jacoby

From: asco.org ASCO Perspective “This study, which never would have happened without federal funding for cancer research, will transform care immediately, and for the better. These data provide critical reassurance to doctors and patients that they can use genomic information to make better treatment decisions in women with early-stage breast cancer. Practically speaking, this means that thousands of women will be …

View Post

FDA chief outlines new ways to speed cancer drug approvals

In In The News by Barbara Jacoby

By: Julie Steenhuysen From: reuters.com The U.S. Food and Drug Administration is taking steps to streamline the approval process for cancer drugs, reviewing clinical trial data up front to make sure applications companies submit are complete. The new approach, outlined on Saturday in a speech by FDA commissioner Dr. Scott Gottlieb at the American Society of Clinical Oncology (ASCO) meeting in …

View Post

A Biotech Executive Faces End-Stage Cancer As A Patient

In In The News by Barbara Jacoby

By: Matthew Herper From: forbes.com For years, Michael Becker was one of the drug executives navigating swarms of cancer doctors at the annual meeting of American Society of Clinical Oncology, where 40,000 people gather every year to talk about the hottest cancer-killing drugs. This year he came back, but it was very different. This time he spoke to an audience of …

View Post

Consider This a Warning on Cancer-Drug Combos

In In The News by Barbara Jacoby

By: Max Nisen From: bloomberg.com The hype over these treatments has dramatically outpaced delivery. The pharmaceutical industry believes that the lucrative future of cancer treatment lies in combining immune-boosting medicines with other drugs to boost their effectiveness. But that future is still a ways off, and the present is pretty ugly. It’s something to keep in mind as one of the year’s biggest cancer …

View Post

Circulating Tumor Cells To Help Stage Metastatic Breast Cancer, New Research To Be Featured at ASCO Annual Meeting

In In The News by Barbara Jacoby

Study adds to significant body of evidence supporting clinical utility of CELLSEARCH Bologna, Italy and Huntingdon Valley, Pa., MAY 30, 2018 — Menarini Silicon Biosystems announced today that a new study has found that using circulating tumor cells (CTCs), a form of liquid biopsy, holds promise as a key tool for developing a staging system that can have a significant impact in …

View Post

Essential Eyebrow Solution® will meet with leading oncologists to discuss options for eyebrow hair preservation during cancer treatment

In In The News by Barbara Jacoby

EES – Essential Eyebrow Solution®, EES is the only cosmetic eyebrow product on the market proven to help combat eyebrow thinning.  It has been clinically tested for retention of eyebrows during chemotherapy with outstanding results. RMV Trademarks, LLC, manufacturer and distributor of EES, will be participating in the American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6 at McCormick …

View Post

Here’s What’s Next For Cancer-Killing T-Cells After Strong ASCO Showings

In In The News by Barbara Jacoby

By: Arlene Weintraub From: forbes.com The big news about chimeric antigen receptor T-cells (CARTs) at the American Society of Clinical Oncology meeting that just concluded in Chicago is that there was no earth-shattering news. Some analysts feared that predictions of FDA approvals as early as 2017 would prove overly optimistic for the technology, which involves removing immune-boosting T-cells from patients, …

View Post

Bristol-Myers Squibb Will Win Big with Melanoma Combination Immunotherapy, says GlobalData Analyst

In In The News by Barbara Jacoby

Bristol-Myers Squibb’s Opdivo/Yervoy immunotherapy combination likely to shape metastatic melanoma treatment landscape once approved Key opinion leaders ‘are enthusiastic about the efficacy of the combination, and foresee it as the future standard of care,’ says analyst Data presented at the recent American Society of Clinical Oncology (ASCO) Annual Meeting 2015 by Bristol-Myers Squibb (BMS) suggests that its Opdivo/Yervoy combination of …

View Post

New drugs from Bristol, Merck at forefront of cancer meeting

In In The News by Barbara Jacoby

By Deena Beasley and Bill Berkrot From: reuters.com New data to be released this weekend should help deepen the understanding of how broadly new drugs that unleash the body’s immune system to fight cancer can be used. Results from key clinical trials will be presented starting Friday in Chicago at the annual meeting of the American Society of Clinical Oncology. …